Delpor on track with schizophrenia implant late-stage trials
The company plans to conduct several trials with its drug-device combo in schizophrenia and opioid use disorder over the next couple of years. by Urtė Fultinavičiūtė Delpor is sketching out [...]
Delpor’s Investigational Risperidone Implant Product Provides Schizophrenia Therapy for up to One Year after a Single Administration in Phase 1b/2a Patient Study
Topline results of the Phase 1b/2a study were presented during a poster session at the 2023 Neuroscience Education Institute (NEI) Congress Delpor’s drug/device combination risperidone implant (DLP-114) was well tolerated [...]
Delpor Announces First Subjects Dosed in Phase 1 Clinical Trial of Once or Twice-Yearly Naltrexone Implant for Opioid Addiction
If approved, Delpor’s naltrexone implant is expected to offer a major advancement in the treatment of opioid use disorder by improving medication adherence and reducing relapses. BRISBANE, CA, April 19, [...]
Delpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine Implant
Company expects to enter clinic by 2023 and if approved, Delpor’s tizanidine implant will be the first minimally invasive, long-acting therapy for the maintenance of moderate to severe spasticity Expanded [...]
Delpor Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Once-Yearly Risperidone Implant
If approved, Delpor’s risperidone implant will be the first once-yearly schizophrenia maintenance therapy. BRISBANE, CA, April 22, 2021 — Delpor, Inc. (Delpor), a clinical-stage biopharmaceutical company that utilizes innovative technologies [...]
Delpor Appoints Jay Smith as Chief Commercial Officer to Lead Commercialization of Once-Yearly Risperidone Implant
Smith will also be responsible for optimizing customer experience for Delpor’s implant products, as he oversaw over 23k procedures for another implant biotech BRISBANE, CA, March 31, 2021 — Delpor, [...]